Real-Time Content, Celebrity Wishes, Stories and Media Access Begins July 5th
WASHINGTON, July 3, 2025 /PRNewswire/ -- On July 6, millions worldwide will unite in celebration...
SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on July 2, 2025 the Company granted (i) non-qualified stock options to one newly-hired non-executive employee to purchase a total of 30,000 shares of the Company’s common stock at an exercise price per share of $1.12, which was the closing price per share of the Company’s common stock as reported by NASDAQ on July 2, 2025, the options grant date, and (ii) restricted stock units (RSUs) representing 37,900 shares of its common stock to two newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company’s Board of Directors and granted under the Company’s Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years, with 25% of the shares underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% vesting in approximately equal monthly installments over the following thirty-six months, subject to the employee being continuously employed by the Company through each vesting date. The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employees being continuously employed by the Company through each vesting date.
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) between January 14, 2021 and June 5, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 29, 2025.
LIVINGSTON, N.J., July 3, 2025 /PRNewswire/ -- CoreWeave (Nasdaq: CRWV), the AI Hyperscaler™, today announced it is the first AI cloud provider to deploy the latest...
Ownership of Pension Insurance Corporation Group ("PICG"), ultimate parent company of the specialist insurer of UK defined benefit pension schemes Pension Insurance Corporation ("PIC"),...
New electricity generation projects will help meet customers' growing energy needs and support economic development
KELOWNA, BC, July 3, 2025 /CNW/ - FortisBC Inc. (FortisBC)...
NEW YORK, July 3, 2025 /PRNewswire/ -- The promotion and information campaign "Discover the European Cheestories with cheeses from Spain", promoted by the Interprofessional Dairy...
SIGGRAPH's Student Volunteer program empowers the next generation of leaders in computer graphics and interactive techniques.
VANCOUVER, BC, July 3, 2025 /PRNewswire/ -- Long recognized as...
NEW YORK, July 3, 2025 /PRNewswire/ -- The promotion and information campaign "Discover the European Cheestories with cheeses from Spain", promoted by the Interprofessional Dairy...
MORTON GROVE, Ill., July 3, 2025 /PRNewswire/ -- Lifeway Foods, Inc. (NASDAQ: LWAY) ("Lifeway" or the "Company"), a leading U.S. supplier of Kefir and fermented...
TORONTO, July 3, 2025 /CNW/ - The 3rd Transatlantic Symposium on Sustainable Development in Higher Education, hosted by International Business University (IBU) in Toronto,...
The global robotic surgery market size is calculated at USD 13.79 billion in 2025 and is expected to reach around USD 54.66 billion by 2034, growing at a CAGR of 16.54% for the forecasted period.
The global robotic surgery market size is calculated at USD 13.79 billion in 2025 and is expected to reach around USD 54.66 billion by 2034, growing at a CAGR of 16.54% for the forecasted period.